Teva launches generic breast cancer, osteoporosis drug

Teva has 180 days of marketing exclusivity for generic Evista, which had 2013 US sales of $824 million.

Teva Pharmaceutical Industries Ltd. (NYSE: TEVA; TASE: TEVA) has received approval from the US Food and Drug Administration (FDA) to market the generic equivalent to 60 mg Evista (Raloxifene) tablets. Teva was first to file, making the product eligible for 180 days of marketing exclusivity, and the company will begin shipping the product within the next 30 days.

Evista marketed by Eli Lilly and Co., had annual sales of approximately $824 million in the US, according to IMS data as of December 2013. Raloxifene is an oral selective estrogen receptor modulator (SERM) that has an estrogenic effect on bone and anti-estrogenic effects on the uterus and breast. In this manner it prevents osteoporosis in postmenopausal women and reduces the incidence of breast cancer in postmenopausal women.

Published by Globes [online], Israel business news - - on March 4, 2014

© Copyright of Globes Publisher Itonut (1983) Ltd. 2014

View comments in rows
Update by email about comments talkback
Twitter Facebook Linkedin RSS Newsletters גלובס Israel Business Conference 2018